Clinical trials: Allogeneic Stem-Cell Transplant
Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin…
- Trial name
- NCT06705062
- Testing
- reduced-dose PTCy, Standard dose PTCY
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
This phase II trial studies how well ibrutinib works in preventing acute leukemia in patients after reduced-intensity conditioning and stem cell transplant.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03267186
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Andrew Rezvani
Acute Myeloid Leukemia (AML)
Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML
1. To evaluate whether stem cell transplantation from a matched sibling donor is equivalent to a matched unrelated donor in in a second complete remission of acute myeloid leukemia (AML). 2.
- Trial name
- NCT00606723
- Testing
- Hematopoietic stem cells from bone marrow or peripheral blood
- Where
- 24 sites in Austria, Czechia and 1 more
- Volunteers
- 154 people
- Sponsor
- Hannover Medical School
Oral Mucositis
Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients
Patients receiving high-dose chemotherapy/conditioning prior to stem cell transplantation (SCT) are at high risk for developing painful lesions in the oral cavity, known as oral mucositis (OM).
- Trial name
- NCT03490396
- Testing
- Gelclair, First® Mouthwash BLM
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Midatech Pharma US Inc.
Neuroepithelial Tumor, Solid Tumor
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
There is currently no standard treatment for patients with neuro-epithelial (brain) or other solid tumors in another part of the body who do not have adequate suitable autologous hematopoietic progenitor cells available and/or…
- Conditions
- Neuroepithelial Tumor, Solid Tumor, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT02653196
- Testing
- Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy, Keratinocyte Growth Factor, Alemtuzumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Lymphoma
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Giving high doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00521261
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Disorder Related to Bone Marrow Transplantation
Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children
Children treated by bone marrow transplantation (BMT) experience bone toxicity. Those bone damages are caused by both a decrease of bone formation and an increase of bone destruction after BMT.For long term survivors, bone…
- Trial name
- NCT02677246
- Testing
- Denosumab
- Where
- Canada
- Sponsor
- St. Justine's Hospital
Septic Shock
Pentaglobin in CRE and PA Neutropenic Infections
To demonstrate that the early addition of Pentaglobin to the best available antimicrobial therapy is able to reduce mortality and improve survival in neutropenic febrile acute leukemia or allo- Hematopoietic stem cell…
- Trial name
- PENTALLO (NCT03494959)
- Testing
- Pentaglobin
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Leukemia, Myelodysplastic Syndrome
Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease
The purpose of this study is to study the pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Leukemia, Myeloid, Acute
- Trial name
- ANIDULAPK (NCT01249820)
- Testing
- anidulafungin 200 mg q48h, anidulafungin 300 mg q72h
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Radboud University Medical Center
Allogeneic Stem Cell Transplantation
Caphosol® Versus State-of-the-art Mouthcare in Patients With Allogeneic Stem Cell Transplantation: a Randomized Controlled Study About the Efficacy of the Mouth Rinse Caphosol®
Randomized controlled study about the efficacy of the mouth rinse Caphosol in patients with allogeneic stem cell transplantation. 85% of the patients receive a severe oral mucositis due to their treatment.
- Trial name
- NCT01758562
- Testing
- Caphosol
- Where
- Switzerland
- Volunteers
- 72 people
- Sponsor
- University of Zurich
Hematological Cancer
Evaluation of the Impact of Sports-inspired Onco-coaching on Health-related Quality's Life of the Patients in Cancer Remission After Allogeneic Transplantation of Hematopoietic Stem Cells
To measure the impact of a coaching program on the patient's health-related quality of life 15 months post-transplant (M15/R12).
- Trial name
- NCT05486273
- Testing
- interviews with coachs, semi-structured interviews and questionnaires, semi-structured interviews and questionnaires
- Volunteers
- 108 people
- Sponsor
- Institut Paoli-Calmettes
Invasive Aspergillosis
Impact of Pre-existing Invasive Aspergillosis on Allogeneic Stem Cell Transplantation
Via a prospective non-interventional study clinical outcome of patients with - and without - history of pre-existing invasive aspergillosis undergoing allo-HSCT will be assessed, in terms of non-relapse mortality overall…
- Trial name
- IPAT (NCT03014934)
- Where
- 8 sites in Germany, Italy and 4 more
- Volunteers
- 2,100 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Failure of Bone Marrow Graft
Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant
This phase I/II clinical trial will test the safety and the efficacy of post transplant administration of plerixafor in enhancing hematological recovery in humans.
- Trial name
- NCT01280955
- Testing
- Plerixafor
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Mitchell Horwitz, MD
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)
This study is a prospective multicenter observational study to evaluate the feasibility and the efficacy of the conditioning regimens which are modified by the donor differences and the age of recipients among patients who will…
- Trial name
- ATLAS2015 (NCT02428517)
- Testing
- AlloHCT for Young/MSD, AlloHCT for Young/MUD&FMD, AlloHCT for Old/MSD
- Where
- 4 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center
Umbilical Cord Blood, Stem Cell Transplantation
Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)
The aim of this study is to evaluate the safety profile and tolerability of infusion of cord blood cells expanded in the lab and to evaluated whether through the infusion of expanded cells it is possible to expedite engraftment…
- Conditions
- Umbilical Cord Blood, Stem Cell Transplantation, Hematological Malignancies
- Trial name
- NCT01235468
- Testing
- ex vivo expansion
- Sponsor
- Dr. Avichai Shimoni MD
Chronic Graft Versus Host Disease
Multiple Donor Treg DLI for Severe Refractory Chronic GVHD
This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS. The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC…
- Trial name
- TREG2015001 (NCT02749084)
- Testing
- T reg DLI
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Mario Arpinati
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
The hypothesis of this study is that lenalidomide can be an effective drug in preventing relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q after allogeneic HSCT.
- Trial name
- LENAMAINT (NCT00720850)
- Testing
- lenalidomide
- Where
- 7 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Technische Universität Dresden
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation, Hematologic Disorders
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic…
- Trial name
- NCT07483385
- Testing
- Lusutrombopag
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The General Hospital of Western Theater Command
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.